Peptides, Medtech, and the Obesity Treatment Market

18 months ago, weight-loss peptides looked like they might fundamentally reshape healthcare demand patterns overnight. Investors treated semaglutide and tirzepatide as existential threats to multiple device categories, from cardiovascular technologies to orthopedics, diabetes management, and surgical interventions. Today, the latest data suggests the obesity treatment market is evolving in a more complicated way.

The original disruption thesis was directionally understandable. Prescription growth has been extraordinary. But broad assumptions about collapsing device demand have not held up, at least not yet.

The Numbers Behind the Shift

Use of GLP-1 therapies among overweight or obese adults surged 587% between 2019 and 2024.

As of 2025, an estimated 13% of U.S. adults are using these therapies specifically for weight loss, compared with roughly 6% in early 2024.

That kind of adoption curve is difficult to ignore.

But has it materially changed obesity prevalence?

Yes, though not dramatically.

U.S. obesity rates peaked at approximately 40% in 2022. By 2025, that figure had declined to 37%, representing about 7.6 million fewer obese adults.

That sounds meaningful, but context matters. A 37% obesity rate essentially returns the U.S. to pre-pandemic levels rather than signaling a structural reversal of the broader obesity burden.

Diabetes prevalence tells a similarly sobering story. In 2025, 13.8% of U.S. adults were diagnosed with diabetes, compared with 10.6% roughly a decade earlier.

So while these therapies are having an effect, the underlying disease burden remains substantial.

At a glance:

  • 587%+ growth in GLP-1 prescriptions (2019–2024)
  • 12.4% of U.S. adults currently using GLP-1s for weight loss
  • ~3% decline in obesity prevalence from 2022 to 2025
  • 90% to 95% of severely obese patients still receiving no obesity treatment

Where Medtech Has Actually Felt the Impact

Most major medtech sectors have remained resilient.

The most obvious exception is bariatric surgery.

A 2025 JAMA Surgery analysis reported a 46% drop in bariatric procedures among eligible patients between 2022 and 2025. More recently, data presented at the 2026 ASMBS annual meeting showed bariatric and metabolic procedure volumes fell below 200,000 in 2024 for the first time since 2020, marking a 20% year-over-year decline.

This is real disruption.

Even so, the picture inside bariatrics is not entirely one-directional. Gastric bypass procedures have increased, suggesting some patients who initially pursued pharmacologic treatment may be returning to surgery when drug-based outcomes prove insufficient.

Outside bariatrics, the feared collapse in demand has not emerged. Cardiovascular technologies, diabetes management tools, and surgical robotics continue to attract capital and strategic interest.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/peptides-medtech-and-the-obesity-treatment-market

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more